FDA Brief

Warning letters Food

FDA warning letter to

Time Challenger Labs International, Inc.

High riskIssued Sep 18, 2025Posted Sep 30, 2025Human Foods Program

Time Challenger Labs was warned for unapproved drug claims on five supplements and serious manufacturing violations.

What happened

FDA inspected the Round Rock, TX facility on December 18 – 19, 2024, and reviewed the website in May 2025. It found no finished-product or component specifications, no master manufacturing or batch records, and no written quality-control procedures; several were repeat observations from 2021. FDA also found website claims that five products treat diseases and that the Resveratrol label lacked required dietary supplement and botanical-source information.

What FDA found

  1. The company did not set finished-product specifications for identity, purity, strength, composition, and contaminant limits, a repeat observation.

    21 CFR 111.70(e)
  2. The company did not set component identity specifications and other necessary specifications for the dietary ingredients it uses.

    21 CFR 111.70(b)
  3. The company had no master manufacturing records for its dietary supplements, a repeat observation.

    21 CFR 111.205(a)
  4. The company did not prepare batch production records when it made dietary supplement batches.

    21 CFR 111.255(a)
  5. The company had no written quality-control procedures and its quality-assurance SOP had not been implemented, a repeat observation.

    21 CFR 111.103
  6. The Resveratrol label did not identify the product as a dietary supplement or name the plant parts used for botanical ingredients.

    21 U.S.C. 343(s)(2)(B), (s)(2)(C); 21 CFR 101.3(g), 101.4(h)(1)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of steps taken to correct violations and prevent recurrence, with documentation, or explain why it cannot complete them and when it will.

Who should pay attention

  • retailers that stock or list these supplements
  • supplement brands using contract manufacturers with similar manufacturing gaps
  • consumers who use supplements marketed with disease claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk